CoChat

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)

Open access
Skalniak, Lukasz, Surmiak, Ewa, Holak, Tad A. · 2019 · Expert Opinion on Therapeutic Patents
Cited by 43

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Introduction: MDM2 and MDMX proteins provide the inhibition of p53 tumor suppressor, thus allowing for accelerated mutation-driven cancer microevolution. A pharmacological blockade of MDM2/X-p53 interaction results in p53 reactivation in p53wt cells, leading to cancer growth inhibition. Throughout the past 20 years, multiple chemical entities have been proposed to reactivate p53 by antagonizing MDM2/X proteins.Areas covered: This manuscript reviews 2014–2018 therapeutic patents in the field of MDM2/X antagonists and is a continuation of previous reviews on similar matter. The patents covering the use of MDM2/X antagonists in drug combinations are also presented in this review, as they constitute an important trend in the field of cancer treatment with MDM2/X antagonists.Expert opinion: In the years 2014–2018, several previously-known chemical scaffolds have been further developed and disclosed. Importantly, in the same time period, many lead compounds have entered clinical trials for the treatment of cancer patients. Meanwhile, several important reports have pointed to serious limitations of anticancer properties of MDM2 antagonists. As a result, many efforts have been made to seek for positive, synergistic therapeutic effects of combined anti-cancer treatment strategies. One recent example is a dual targeting of MDM2 and additional protein targets by utilizing the PROTAC technology.Trial registration: ClinicalTrials.gov identifier: NCT02264613.Trial registration: ClinicalTrials.gov identifier: NCT02624986.Trial registration: ClinicalTrials.gov identifier: NCT02670044.Trial registration: ClinicalTrials.gov identifier: NCT02545283.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/13543776.2019.1582645

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 43

Metadata

Authors
Skalniak, L., Surmiak, E., & Holak, T. A.
Venue
Expert Opinion on Therapeutic Patents
Published
2019-03-01
Volume
29
Issue
3
Pages
151-170
ISSN
  • 1354-3776 (ISSN-L)
  • 1744-7674
OpenAlex
W2918753187
Cited by
43
References
25
FWCI
2.27
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018). https://app.cochat.ai/papers/10.1080/13543776.2019.1582645
The paper
Skalniak, L., Surmiak, E., & Holak, T. A. (2019). A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2019.1582645

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.